Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that azathioprine treatment in Korean children with inflammatory bowel disease frequently led to adverse events, with bone marrow suppression being the most common.

This study found that blocking GABA(A) receptors in cat dorsal horn neurons increased evoked activity and background discharge, highlighting differences in inhibitory control systems compared to glycine receptors.

This study found that applying BPM 31543 twice daily was safe, well-tolerated, and showed signs of reducing chemotherapy-induced alopecia in women receiving taxane-based chemotherapy.

In this study, alopecia areata patients treated with diphencyprone showed a significant increase in CD8 lymphocytes around hair bulbs, which may be associated with hair regrowth.

This study suggests that cutaneous adverse reactions to bortezomib and lenalidomide are more frequent than reported, impacting patients' quality of life and may require dermatological consultation for proper management.

In this study, withdrawal of baricitinib therapy in patients with severe alopecia areata who had achieved hair regrowth led to a loss of benefit in almost all patients, suggesting that continued treatment is necessary to maintain hair regrowth.

In this review, the authors noted that while baricitinib, a treatment for refractory rheumatoid arthritis and severe alopecia areata, shows promising efficacy, it may pose risks of serious infections and malignancy due to immune downregulation.

This study found that MK-5108 is well tolerated at high doses as monotherapy in cancer patients, showing stable disease and some antitumor activity, particularly in combination with docetaxel.

Using PDRN injections and RF treatments improved revision nose surgery results without major side effects.

This study found that early treatment of alopecia areata with JAK inhibitors can improve patients' physical and psychological quality of life without worsening skin lesions associated with sarcoidosis.

This study reported that in a case series of three adolescents with alopecia areata and atopic dermatitis, treatment with 15 mg/day of upadacitinib led to rapid improvement in skin symptoms and significant hair regrowth over 12 months, with no severe adverse events observed.

This case report describes a 14-year-old girl with alopecia universalis and mild atopic dermatitis who achieved complete hair regrowth and eczema resolution after three months of treatment with the JAK1 inhibitor upadacitinib.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.

This study reported that 80% of patients with non-scarring alopecia showed a clinical cure after treatment with unactivated platelet leukocyte autoplasma.

This study found that some patients with alopecia areata who did not respond to ritlecitinib treatment by Week 24 achieved a positive response with continued therapy by Week 48, with tolerable side effects.

This study found that administering botulinum toxin A via Flex-PADs to mouse footpads inhibited sweating similarly to traditional injections, suggesting a promising patient-friendly delivery method for hyperhidrosis treatment.

This study reports that a novel bioabsorbable nano-micelle hybridized hydrogel scaffold may reduce postoperative melanoma recurrence and mitigate the side effects of doxorubicin in mouse models.

This case report describes a 69-year-old woman who developed drug-induced acquired ichthyosis related to ponatinib therapy, which improved upon stopping the medication.

This study observed an increased risk of alopecia areata among new users of GLP-1 agonists semaglutide and liraglutide compared to users of bupropion-naltrexone, highlighting potential hair loss concerns with these medications.

In this study, finasteride altered the expression of nine proteins in the rat nucleus accumbens, suggesting new therapeutic targets and mechanisms for its effects on neuropsychiatric conditions.

This study demonstrates that bioequivalence for proposed 50-mg ritlecitinib capsules versus clinical 100-mg capsules can be supported using a PBPK model-based biowaiver, achieving over 90% probability of success.

Medroxyprogesterone acetate improved sleep apnea symptoms in some obese patients.

This review discusses chemoprevention for prostate cancer and suggests that further open and unbiased investigation into various preventive compounds, including 5α-reductase inhibitors, is needed.

This study established a stable cell line for CRF1 receptor screening, which can be used to develop functional cosmetics and modulators potentially affecting hair re-growth.

This study found that while the carboplatin-paclitaxel regimen for advanced lung cancer is more affordable than newer treatments and maintains a good performance status, it significantly increases risks of alopecia and peripheral neuropathy.

This article discusses the introduction and market presence of the Italian hair product Kevis but presents no new clinical findings.

In this study, researchers observed that phospholipid-calcium carbonate hybrid nanoparticles effectively delivered Tofacitinib citrate topically, which significantly inhibited hair follicle apoptosis and promoted hair growth in a mouse model of chemotherapy-induced alopecia, compared to a traditional Tofacitinib solution.